Carlsmed Sues DeGen Medical for Patent Infringement
News related to:Carlsmed, Inc · 1 min read
CARLSBAD, Calif., Sept. 15, 2026 /CourierPR/ -- Carlsmed, Inc., a medical technology company specializing in AI-enabled personalized spine surgery solutions, has filed a patent infringement lawsuit against DeGen Medical, Inc. The lawsuit, filed in the United States District Court for the District of South Carolina Florence Division, alleges that DeGen is infringing on eight of Carlsmed’s patents related to its implants, methods, and systems.
Mike Cordonnier, Chairman and CEO of Carlsmed, stated, "Carlsmed is dedicated to advancing the standard of care in spine surgery through our proprietary personalized spine surgery solutions and bringing value to patients, surgeons, and payors every day. We are committed to protecting the intellectual property that supports our patient-centric innovation, which remains at the forefront of the industry."
The complaint seeks injunctive relief and damages for infringement. Carlsmed’s legal action underscores its commitment to safeguarding its intellectual property and ensuring that its innovations are not misappropriated by competitors.
Carlsmed, Inc., founded with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond, has been at the forefront of AI-enabled personalized spine surgery solutions. This legal action is part of the company’s ongoing efforts to uphold its intellectual property rights and maintain its competitive edge in the medical technology sector.
The lawsuit highlights the growing importance of intellectual property in the medical technology industry, where companies are increasingly investing in innovative solutions to improve patient care and outcomes. Carlsmed’s legal move against DeGen Medical, Inc., serves as a reminder of the competitive landscape and the need for companies to protect their proprietary technologies.
As the legal proceedings unfold, stakeholders in the medical technology sector will be closely watching the outcome, which could have significant implications for both Carlsmed and DeGen Medical, as well as the broader industry.